Answers are grounded in this paper and cite their sources.
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent and underdiagnosed among young healthy adults, with or without metabolic syndrome. This study assessed whether the Fibrosis-4 Index (FIB-4) in young healthy adults is associated with incident end-stage liver disease (ESLD). METHODS: This retrospective study was conducted using a nationwide community and hospital database. Included were young adults, ages 18-40 years, with a FIB-4 score calculated during 2005-2020. People diagnosed with liver metastasis or chronic liver disease, other than MASLD, before or during the study, were excluded. The primary outcome was the first diagnosis of cirrhosis, cirrhosis-related complications, or hepatocellular carcinoma. Cox proportional models were applied, with FIB-4 score categorized by percentiles. RESULTS: There were 430 incident cases of ESLD in 11,057,421 person-years (mean age at diagnosis 30.0 ± 5.3 years). FIB-4 score was associated with incident ESLD. After adjusting for multiple confounders, people with FIB-4 in the 75th-94th, 95th-98 th , and ≥ 99th percentiles were 35%, 140%, and 760% more likely to develop ESLD, respectively, compared with people with FIB-4 score in the 5th-49th percentiles. Each point of FIB-4 score was associated with a 2.2-fold greater risk of incident ESLD (adjusted hazard ratio 2.21, 95% confidence interval 1.91-2.56). DISCUSSION: FIB-4 score is associated with increased risk of ESLD in young healthy adults.
No takes yet. Share an insight, caveat, or question.
Meron et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: